Navigation Links
Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
Date:9/20/2008

ENEFIT is the first and only prospectively planned five-year MS study to demonstrate the long-lasting benefits of initiating Betaseron (interferon beta-1b) after the first clinical event suggestive of MS. Overall, results from the trial showed that early initiation of Betaseron treatment in patients with the earliest signs of the disease delayed the progression to CDMS and McDonald MS, and improved cognitive function as measured by PASAT.

The multi-center trial was conducted at 98 sites in 20 countries and included patients presenting with a single clinical episode suggestive of MS. A total of 468 patients with a first clinical demyelinating event suggestive of MS and typical MRI findings were randomized to receive either 250 micrograms of Betaseron every other day or placebo as a subcutaneous injection in a double blind fashion for a maximum of two years. The study was designed to encompass a representative population of patients with the earliest signs of MS, including patients with mono- or multifocal lesions.

The placebo-controlled treatment period lasted up to 24 months or up to the time when patients were diagnosed with clinically definite MS. All study participants were then invited to participate in a follow-up study with Betaseron to prospectively assess the impact of such early versus delayed treatment with Betaseron on the long-term course of the disease for a total observation time of five years.

"Early treatment" refers to treatment initiated after the first clinical event; "delayed treatment" refers to treatment initiated after the second clinical event or after two years, whichever occurs first.

About Betaseron

Betaseron is indicated for the treatment of relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations. Patients with multiple sclerosis in whom efficacy has been demonstrated include patients who have experienced a first clinical episode and have MRI features consistent with multi
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
2. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
3. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
4. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
5. Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
6. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
7. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
8. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
9. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
10. New Clinical Studies Confirm Mauna Kea Technologies Cellvizio(R) GI in Range of Procedures
11. IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... Pennsylvania , 21 de noviembre de 2014 ... de ensayos clínicos externalizados y tecnologías eClinical, ha ... aproximación de ,seguimiento inteligente, para el seguimiento basado ... seguimiento inteligente amplía el concepto del seguimiento basado ... reducción de las visitas de seguimiento o cambio ...
(Date:11/22/2014)... , Nov. 21, 2014 Research and ... Recombinant Protein Drug Industry Report, 2014-2017" report to ... The Chinese recombinant protein drug market has ... rigidity, consumption ability and the like. During 2005-2013, sales ... grew at a CAGR of 19.1%, and it is ...
(Date:11/21/2014)... DIEGO , Nov. 21, 2014  Tandem ... TNDM ), a medical device company and manufacturer ... announced a partnership with Tidepool, a non-profit dedicated ... open source software platform that increases diabetes data ... Tidepool Platform, which is currently under development, to ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
... 2012 Pharmspective, LLC today announced the release ... - specifically developed to analyze provisions in the ... key pharma customer decision makers who influence product ... research firm providing knowledge management applications to the ...
... March 7, 2012, at 8:30 a.m. Eastern/2:30 p.m. Central ... (NASDAQ and MTA: CTIC) management team will host a ... and year-end achievements and financial results. ... Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time 1-877-941-8609 ...
Cached Medicine Technology:Pharmspective Announces the Release of ClearView™ - a New Health Care Reform Knowledge Management Web Application for the Biopharma Industry 2
(Date:11/22/2014)... 2014 (HealthDay News) -- Those air-blown hand dryers in ... paper towels, a new study suggests. British researchers ... of volunteers in order to simulate poorly washed hands. ... dryers or paper towels to dry their hands. ... amounts of germs around both types of dryers than ...
(Date:11/22/2014)... Amy Norton HealthDay Reporter ... live in nursing homes may commonly deal with aggressive or ... The study of 10 centers in New York state found ... percent of residents were involved in some type of incident ... verbal clash, with someone yelling or cursing at another resident. ...
(Date:11/21/2014)... Lauderdale, FL (PRWEB) November 21, 2014 Body ... services announced that it accepts Spafinder massage gift cards ... and in room hotel massage in all service areas including ... you don't have to go to the spa at all ... Owner and Founder of Body Well. "We may not be ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Certain genes ... in up to a fifth of people with type ... has long been pondered by doctors working with diabetic ... have been under the impression that exercise helps decrease ... Dr. Maria Pena, director of the Center for Weight ...
(Date:11/21/2014)... 2014 MLF Biotech, Inc. has developed ... Liv-Pro® Probiotics for Pets helps maintain digestive health and ... pet's intestinal flora after it experiences a period of ... Probiotics for Pets is a proprietary blend of pure ... live active bacteria strains that are safe and effective ...
Breaking Medicine News(10 mins):Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2
... Patients with a certain gene variant drank less ... without the variant while taking the medication naltrexone, ... National Institutes of Health,s 2001-2004 COMBINE (Combined Pharmacotherapies ... About 87 percent of patients with the variant ...
... Fourth Consecutive Quarterly ... Revenue Increase Over Prior Year, SAN DIEGO, Feb. 7 ... today reported financial results for its fourth quarter and,fiscal 2007. Operating ... Vermed which was sold on August 31, 2007., Key Financial ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... President & Chief Executive Officer. In support of ... MPM,Capital, Great Point Partners, Oxford Biosciences and Venrock, ... who has served as the,Company,s President & Chief ...
... Finding Health and Mental Health Top the List,of Needs, ... series of tornadoes in decades, many people across the ... Cross continues to help,provide meals, shelter and clean up ... welcome help comes from Red Cross health and mental,health ...
... products for infants , , THURSDAY, Feb. 7 (HealthDay News) ... Canada are calling for a ban on the use ... toddler sippy cups, water bottles and other food and ... polycarbonate bottles [investigated in the study] leached BPA when ...
... What began as a healthy family,recipe for a ... people of all,ages. Triathlete Erin DeMarines, founder of 10-year-old ... 3Bar might have gotten its,start with DeMarines, "friends and ... now available in over 200 retail stores including Publix ...
Cached Medicine News:Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 2Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 4Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 5Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 6Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 7Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 3Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 4Health News:Tornado-Scarred States Receive American Red Cross Health Services 2Health News:Tornado-Scarred States Receive American Red Cross Health Services 3Health News:Report Shows Dangerous Chemical Can Leach From Baby Bottles 2Health News:Report Shows Dangerous Chemical Can Leach From Baby Bottles 3Health News:New Natural Energy Bar Hits the Road with Dieters & Athletes Alike 2
... The BD Macro-Vue RPR (Rapid ... and Tear-drop Tests are nontreponemal testing ... syphilis described in A Manual of ... in this manual are the most ...
Rapid Plasma Reagin (RPR) set is a non-treponemal flocculation test that is,used for the qualitative and semi-quantitative determination of reagin,antibodies in serum or plasma from persons with syph...
Enzyme Immunoassay for the quantitative ( qualitative 0020, on request) determination of IgG Class antibodies to Rubella virus....
Donor Screen & Confirmation Kit...
Medicine Products: